drugset / Trial / NCT07466160

A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors

NCT07466160

Phase 1/2 Recruiting 280 enrolled Mabwell (Shanghai) Bioscience Co., Ltd.
Non-randomizedSequentialOpen-labelTreatment

Summary

This study was designed to evaluate the efficacy and safety of 7MW3711 in combination with JS207 in subjects with solid tumor.

Timeline

Start
2026-02-11
Primary completion
2027-12-31
Completion
2029-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject 7MW3711 Other / unclassified Intravenous
Subject Carboplatin Small molecule Intravenous
Subject Cisplatin Other / unclassified Intravenous
Subject JS207 Monoclonal antibody Intravenous

Indications